Provided by Tiger Trade Technology Pte. Ltd.

Editas Medicine

2.52
-0.0500-1.95%
Post-market: 2.570.0500+1.98%19:30 EDT
Volume:1.54M
Turnover:3.96M
Market Cap:385.56M
PE:-3.45
High:2.62
Open:2.61
Low:2.52
Close:2.57
52wk High:4.54
52wk Low:1.66
Shares:153.00M
Float Shares:115.00M
Volume Ratio:0.70
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7307
EPS(LYR):-1.8036
ROE:-118.82%
ROA:-23.29%
PB:3.66
PE(LYR):-1.40

Loading ...

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

GlobeNewswire
·
May 26

Editas Medicine Suspends Existing At-The-Market Offering Prospectus

TIPRANKS
·
May 26

Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell

MT Newswires Live
·
May 26

Editas Showcases Promising EDIT-401 Data for Hyperlipidemia

TIPRANKS
·
May 26

Editas Medicine launches underwritten follow-on stock offering with warrants

Reuters
·
May 26

Editas Medicine Announces Proposed Public Offering

THOMSON REUTERS
·
May 26

Editas Medicine presented preclinical data for EDIT-401 at EAS Congress

TIPRANKS
·
May 26

Editas Medicine presents preclinical EDIT-401 data showing about 90% LDL-C reduction in primate study

Reuters
·
May 26

Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

GlobeNewswire
·
May 26

Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)

Simply Wall St.
·
May 15

JonesTrading Keeps Their Buy Rating on Editas Medicine (EDIT)

TIPRANKS
·
May 14

Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study

MT Newswires Live
·
May 14

Editas Medicine Reports New Preclinical Data Demonstrating Progress of Edit-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

THOMSON REUTERS
·
May 14

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

GlobeNewswire
·
May 14

Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD), Tempus AI, Inc. Class A (TEM) and Editas Medicine (EDIT)

TIPRANKS
·
May 08

Editas Medicine Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 06

Analyst Phil Nadeau Reiterates Buy on Editas Medicine, Citing Promising EDIT-401 Data, Strong Cash Runway, and Large Untapped HeFH Opportunity

TIPRANKS
·
May 06

Editas Medicine Q1 net loss narrows

Reuters
·
May 05

Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate

Benzinga Earnings
·
May 05

BRIEF-Editas Medicine Q1 Net Income USD -24.982 Million Vs. IBES Estimate USD -26.5 Million

Reuters
·
May 05